Supreme Court of the United States · Official docket →
Arnold G. Phillips v. Cecilia Abundis, et al.
Paid petition · United States Court of Appeals for the Seventh Circuit, No. 24-1266 · judgment March 24, 2025
Before the decision, well below the 4.1% base rate, with no standout signals pointing toward a grant.
Question presented
a. Why did the United States District Court for the Northern District of Illinois, Eastern Division, twice unilaterally impose the punishments of "Suspension" upon the medical license of Arnold G. Phillips, M.D. without Notice or a Hearing thereby breaching the "Settlement Agreement"? b. Are pills for the performance a Nuclear Medicine Bone Scan available or not available in the United States? c. Are pills for the performance of a Nuclear Medicine Bone Scan available or not available anywhere on this planet? d. Is it in the national interest of the United States for any jurisdiction of the United States to prosecute anyone for not using pills for the performance of a Nuclear Medicine Bone Scan? e. Are provision of pills for performance of a Nuclear Medicine Bone Scan consistent with the United States Atomic Energy Act of 1954 as Amended? f. Have the United States Nuclear Regulatory Commission, or the United States Food and Drug Administration, or the United States Code of Federal Regulations, or the United States Atomic Energy Act of 1954 or any of its Amendments, the most recent Amendment being May 7, 2025, approved, at any time whatsoever, pills for the performance of Nuclear Medicine Bone Scans?
Counsel of record
For petitioner
Arnold G. Phillips
For respondent
Frank Henry Bieszczat
Office of the Illinois Attorney General
Case
Conference history
Distributed for 1 conference
Proceedings
- Oct 06 2025Petition DENIED. Justice Barrett took no part in the consideration or decision of this petition.
- Aug 13 2025DISTRIBUTED for Conference of 9/29/2025.
- Aug 08 2025Waiver of right of respondent Ecilia Abundis, et al. to respond filed.
- Jun 23 2025Petition for a writ of certiorari filed. (Response due September 5, 2025)